GT Biopharma Inc (GTBP)

[BlissTaxi]

TriKE biotechnology is the latest and greatest innovation coming down the Immmuno Oncology pike:

GT Biopharma, Inc’s (GTBP) TriKE technology has shown superior NK cell cytotoxicity against hematologic tumors in preclinical work compared to earlier versions of the drug. TriKEs (Tri-specific Killer Engager) are an off the shelf option that employ a single chain, tri-specific fusion protein that binds to CD16 on natural killer (NK) cells and targets tumor antigens on cancer cells such CD33 in myeloid malignancies. It adds an IL-15 linker which enhances proliferation and activation of NK cells. TriKEs are particularly attractive due to their low cost of manufacture relative to CAR-T therapy and can be used off the shelf without any modifications of autologous cells in the lab. The company is currently in the process of submitting an investigational new drug application (IND) to the FDA for the TriKE in order to launch a Phase I/II trial in 2H:18.